Regeneron's Arcalyst reduces gout flare-ups in Phase III trial

06/9/2010 | Bloomberg Businessweek

Regeneron Pharmaceuticals' gout drug Arcalyst reduced flare-ups by 80% when administered at 160 milligrams once a week, according to a late-stage trial. The company is banking on the success of Arcalyst and two other experimental drugs in late-stage development to earn as much as $2 billion annually.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR